This paper describes the fabrication and characterization of nested Au pyramidal nanoshells. These particles exhibited two plasmon resonances at visible and near-infrared wavelengths that could be manipulated depending on the size of the gap between inner and outer pyramidal shells. We found that larger gaps (30 nm) exhibited much larger Raman scattering responses compared to smaller gaps (5 nm) in the nested pyramidal shells. The SERS-activity of these anisotropic particles can be optimized by adjusting the distances between the inner and outer Au shells.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2812899 | PMC |
| http://dx.doi.org/10.1021/jp910627r | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
REDalign: accurate RNA structural alignment using residual encoder-decoder network.
BMC Bioinformatics
November 2024
Biomedical and Robotics Engineering, Incheon National University, 119 Academy-ro, Incheon, 22012, Yeonsu-gu, South Korea.
Background: RNA secondary structural alignment serves as a foundational procedure in identifying conserved structural motifs among RNA sequences, crucially advancing our understanding of novel RNAs via comparative genomic analysis. While various computational strategies for RNA structural alignment exist, they often come with high computational complexity. Specifically, when addressing a set of RNAs with unknown structures, the task of simultaneously predicting their consensus secondary structure and determining the optimal sequence alignment requires an overwhelming computational effort of for each RNA pair.
View Article and Find Full Text PDFPSRR-MaxpoolNMS++: Fast Non-Maximum Suppression with Discretization and Pooling.
IEEE Trans Pattern Anal Mach Intell
October 2024
Non-maximum suppression (NMS) is an essential post-processing step for object detection. The de-facto standard for NMS, namely GreedyNMS, is not parallelizable and could thus be the performance bottleneck in object detection pipelines. MaxpoolNMS is introduced as a fast and parallelizable alternative to GreedyNMS.
View Article and Find Full Text PDFFirst-in-Human Dose-Escalation Study of the First-in-Class PDE3A-SLFN12 Complex Inducer BAY 2666605 in Patients with Advanced Solid Tumors Coexpressing SLFN12 and PDE3A.
Clin Cancer Res
December 2024
Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, Texas.
Article Synopsis
- - The study aimed to assess the safety and pharmacological effects of BAY 2666605, a new drug designed to trigger a response in cancer cells by promoting the interaction of two proteins, PDE3A and SLFN12.
- - In a first-in-human trial, five patients with specific tumor characteristics received the drug, but the most notable adverse effect was severe thrombocytopenia (low platelet count), affecting three patients, leading to challenges in determining a safe dosage.
- - Ultimately, due to the severe side effects and the lack of positive treatment responses, the trial was halted, as the drug could not establish a therapeutic dose without causing significant safety issues.
First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies.
Clin Cancer Res
December 2024
Regeneron Pharmaceuticals, Inc., Tarrytown, New York.
Purpose: Preclinical data indicate that fianlimab (antilymphocyte activation gene-3) plus cemiplimab (anti-PD-1) enhances antitumor activity. Here, we report prespecified final analyses of the dose-escalation part of a first-in-human, phase 1 study (NCT03005782) of fianlimab as monotherapy and in combination with cemiplimab in patients with advanced malignancies.
Patients And Methods: Adult patients received 1 to 40 mg/kg of fianlimab plus 350 mg of cemiplimab every 3 weeks (Q3W) across various dose-escalation schedules.
Article Synopsis
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!